Right now, biotech is one of the hottest sectors in the marketSince the beginning of October, this sector has been on a tear, driven in part by positive clinical trials of new, experimental therapiesAnother factor driving the rise of biotech is merger activity, such as the $74 billion acquisition of Celgene (CELG) by Bristol Myers Squibb (BMY) . T...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.